USPTO serial 87284571
FROM CODE TO CURE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 23, 2018
- Examiner
- REEVES, APRIL ELIZABETH
- Law office
- TMO LAW OFFICE 124
What this means
Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use. Continue use in commerce and plan for the 10-year Section 8 and 9 renewal.
Need help with FROM CODE TO CURE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kevin D. McCarthy
Kevin D. McCarthy ROACH BROWN MCCARTHY & GRUBER, P.C.424 MAIN STREET1920 LIBERTY BUILDINGBUFFALO, NY 14202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Drug discovery services; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of genetics; research and development in the field of diagnostic preparations; research in the field of pharmacogenetics; conducting clinical trials for pharmaceuticals; pharmaceutical research and development; research and development in the field of pharmaceuticals for the pharmaceutical industry; conducting early evaluations in the field of new pharmaceuticals; research services in the field of proteins, antibodies, microorganisms and cells; research and development services in the field of antibody technology; structural and functional analysis of genomes; DNA screening for scientific research purposes; biochemical research and analysis; laboratory research in the field of pharmaceuticals; research and development services in the field of immunology; medical research in the nature of computerized genetic analysis of DNA | ACTIVE | Oct 31, 2016 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 19, 2023 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jul 19, 2023 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jul 18, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 23, 2023 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jan 23, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Jan 23, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 7, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 7, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 18, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 1, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 30, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 30, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 25, 2017 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Sep 19, 2017 | AAUA | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | — |
| Sep 18, 2017 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 18, 2017 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 18, 2017 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 18, 2017 | IUAA | USE AMENDMENT ACCEPTED | — |
| Sep 12, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 12, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 10, 2017 | ALIE | ASSIGNED TO LIE | — |
| Aug 31, 2017 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Aug 31, 2017 | IUAF | USE AMENDMENT FILED | — |
| Aug 30, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 30, 2017 | EAAU | TEAS AMENDMENT OF USE RECEIVED | — |
| Apr 2, 2017 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2017 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 2, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 26, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 10, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 2, 2017 | NWAP | NEW APPLICATION ENTERED | — |